Target intelligence / Profile preview

Olfactory receptor family 1 subfamily L member 1 (OR1L1)

Target
OR1L1
Molecular classification
G protein-coupled receptor (GPCR), 7-transmembrane domain receptor (subclass of GPCR), Receptor
01

Overview

Olfactory receptor family 1 subfamily L member 1 (OR1L1) is a member of the large olfactory receptor family of G protein-coupled receptors that mediate the sense of smell in humans. OR1L1 is expressed in the olfactory epithelium, where it detects odorant molecules, activates G protein-mediated signal transduction pathways, and generates neuronal signals corresponding to distinct smells. Olfactory receptors share structural features (seven transmembrane domains) with classic neurotransmitter and hormone receptors, but are unique in their diversity, with hundreds of paralogous genes in the human genome. OR1L1 is involved in recognizing specific odorants and is not considered a conventional drug target. It is not linked to major human disease syndromes and does not have known drug or biomarker associations. Clinical interest is generally limited to its fundamental biological role in olfaction rather than pathophysiological or pharmacological applications.

Other names
Olfactory receptor 1L1OR1L1OR1L2OR9-COlfactory receptor 1L2Olfactory receptor 9-COlfactory receptor OR9-27HG23
02

Mechanism of action

For odorants: Binding to receptor initiates conformational change, activates heterotrimeric G protein, leading to intracellular signal transduction and neuronal depolarization in olfactory sensory neurons. For drugs: Not applicable; olfactory receptors are not therapeutic drug targets.

03

Biological functions

Signal transduction (initiates via odorant binding in the nose)Recognition of odorants (sense of smell)G protein-mediated olfactory signalingNeuronal activation of olfactory sensory neurons
04

Disease associations

Other (no major evidence for a direct role in common disorders, but some association studies have implicated OR1L1 in rare conditions like arteriovenous malformations of the brain; this is not considered a classic disease target)Not commonly associated with major disease classes (e.g., cancer, inflammation, neurodegenerative disease, etc.)
05

Safety considerations

None (not a conventional therapeutic target; functional disruption may affect olfaction but not associated with systemic safety concerns)
06

Interacting drugs

None known (no drugs in current clinical use target human olfactory receptors; their endogenous ligands are small organic odorants)
07

Biomarkers

None currently used (these receptors are not used as clinical biomarkers for patient selection nor for efficacy)

Beyond the preview

Go deeper on Olfactory receptor family 1 subfamily L member 1 (OR1L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olfactory receptor family 1 subfamily L member 1 (OR1L1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call